BANGKOK, THAILAND — 27 May 2025 — Zuellig Pharma, a leading healthcare solutions provider in Asia, will introduce Mounjaro® (tirzepatide) in Thailand by the end of May 2025. The drug, developed by Eli Lilly and Company, is designed to treat both type 2 diabetes and obesity. Zuellig Pharma holds the marketing authorization in Thailand and received the rights to distribute and promote the medication earlier this year.
Mounjaro® (tirzepatide) is a once-weekly, prescription-only injection. It is used to help adults with type 2 diabetes who cannot control their condition through diet and exercise alone. It can be taken on its own when metformin is not suitable or used along with other diabetes medications. The drug is also approved for weight management in adults who are obese or overweight and have at least one related health condition, such as high blood pressure, high cholesterol, sleep apnea, heart disease, prediabetes, or type 2 diabetes.
The medicine comes in a convenient prefilled pen called Mounjaro® KwikPen®, available in 2.5 mg, 5 mg, 7.5 mg, and 10 mg doses. This allows doctors to tailor treatment to suit each patient’s needs.
Thailand faces serious challenges from obesity and diabetes. Nearly half of the population—about 48%—is considered obese. The Ministry of Public Health has classified obesity as a Non-Communicable Disease (NCD) because of its strong link to chronic illnesses like type 2 diabetes. In 2024, Thailand’s Department of Disease Control reported that 6.5 million people—around 1 in 10—live with type 2 diabetes.
Diabetes patients often struggle to control their blood sugar and are at risk of severe complications. These include heart disease, kidney damage, vision problems, and foot ulcers that can lead to infections and amputations.
“Obesity and diabetes have become major health issues in Thailand,” said Rehan Saghir, Executive Vice President of Commercialization at Zuellig Pharma. “We are proud to bring Mounjaro® (tirzepatide) to patients in the region. With our experience in regulatory processes and in delivering innovative treatments, we aim to improve access to care, especially for people with chronic metabolic diseases.”
Related Topics:
